GlassScriptPhysician profile
Michael Charles Roach
NPI 1114226735
$8,793.05
in general payments reported to CMS, 2019-2025
30 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $2,968 · 2021: $193 · 2022: $570 · 2023: $1,318 · 2024: $1,178 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,938.34 | 2020-2023 | |
| Viewray Technologies INC | $1,077.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $842.15 | 2019-2025 | Imfinzi, Tagrisso |
| Janssen Scientific Affairs, LLC | $685.18 | 2024-2025 | Rybrevant, Erleada, Balversa |
| Novocure INC. | $355.01 | 2023-2025 | Optune, Optune Gio |
| E.R. Squibb & Sons, L.L.C. | $352.52 | 2020-2025 | Opdivo |
| Elekta, INC. | $348.06 | 2023-2025 | Elekta Medical Linear Accelerator |
| Janssen Biotech, INC. | $313.63 | 2022-2024 | Rybrevant, Erleada, Akeega |
| Regeneron Healthcare Solutions, INC. | $254.13 | 2022-2024 | Libtayo |
| Sumitomo Pharma America, INC. | $251.70 | 2023 | Orgovyx |
| Pfizer INC. | $182.90 | 2020-2023 | |
| Monteris Medical Corporation | $178.98 | 2025 | Neuroblate |
| Siemens Medical Solutions USA, INC. | $163.52 | 2023-2025 | Varian Ethos Treatment Planning, Aria Radiation Therapy Management Software |
| Astellas Pharma US INC | $129.95 | 2025 | Vyloy |
| Springworks Therapeutics, INC. | $125.00 | 2024 | Ogsiveo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.32 | 2024-2025 | Keytruda, Lynparza, Lenvima |
| Novartis Pharmaceuticals Corporation | $95.08 | 2021-2025 | |
| Lilly USA, LLC | $79.61 | 2023-2024 | Zepbound, Jardiance |
| Carbofix Spine INC | $51.94 | 2019 | |
| Medtronic, INC. | $48.18 | 2025 | Superlock |
| Fresenius Kabi USA, LLC | $32.25 | 2023 | Stimufend |
| Reflexion Medical, INC. | $31.41 | 2023 | Reflexion Medical Radiotherapy System |
| Abbvie INC. | $28.65 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $25.05 | 2022 | |
| Servier Pharmaceuticals LLC | $23.25 | 2024 | |
| Teleflex LLC | $21.51 | 2025 | Barrigel |
| Abbott Laboratories | $18.88 | 2023 | Freestyle Libre 2 |
| Seagen INC. | $15.18 | 2023 | Tivdak |
| Johnson & Johnson Surgical Vision, INC. | $12.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.